tried STEP for 14 weeks. here is what happened.
STEP. That is the whole post, but I will justify it.
Everything else people worry about in c/orforglipron is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort STEP out first, and almost nobody does.
I say this having got it wrong for 22 months. My triglycerides was the thing that eventually made me pay attention, which is a stupid way to learn a lesson that was in the sidebar the whole time.
best — the order this archive was captured in
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
SURMOUNT-4 discontinuation arm showed regain.
Adding to this: SURMOUNT is doing more work than the comment implies.
Dead space in the needle hub holds a small but non-trivial volume.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Strongly agree. Phase 2 is investigational, not conclusive.
You have restated the marketing copy. What is the actual substance here.
[deleted]
event rates are more informative than hazard ratios alone
Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.
SELECT reported a SELECT hazard ratio but the absolute event rate is what changes clinical practice.
Strongly agree. Phase 2 is investigational, not conclusive.
STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix
Strongly agree. Phase 2 is investigational, not conclusive.
press release hazard ratio posts must be flaired until a publication exists
Strongly agree. Phase 2 is investigational, not conclusive.
number-needed-to-treat is the house dialect
number-needed-to-treat is the house dialect
Disagree on that part. 98.1% and 96.2% on the same vial is normal.
give the trial name, phase, n, and primary endpoint in the body
Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.
Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.
Removed a chain here. The rule is one line long and it is not negotiable.
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
- 1Dead space in the needle hub holds a small but non-trivial volume. On…5 comments in this branch · started by u/week_one_wanda
- 2Water content matters more than people think. If a vial is carrying residual…5 comments in this branch · started by u/ahmed_iyer